二是主要推荐重点人群接种的疫苗，不同疫苗重点人群是不一样的。比如建议慢性肝病患者、育龄 期妇女、老年人、学生、部队官兵、餐饮业人员，还有畜牧养殖者、以及疫区旅行者等接种戊肝疫苗， 建议出血热高流行区的人员接种出血热疫苗。 三是特定情形下接种的疫苗。比如被犬、猫等狂犬病宿主动物抓咬伤之后，建议接种狂犬疫苗，另 外，根据伤口的情况，以及既往的疫苗接种史来确定是不是需要接种破伤风疫苗。另外，如果是出境旅 行，还需要根据入境国家的要求，可能需要接种黄热病疫苗、霍乱疫苗或者是流感疫苗等。 张丽强调，成人选择疫苗要综合年龄、健康情况、职业、旅行计划、既往疫苗接种史等因素来判 断，具体可以咨询当地的疾控中心或者接种单位。 国家卫健委22日召开新闻发布会，介绍时令节气与健康(处暑)有关情况，并答记者问。会上，有记 者问：疫苗是预防疾病的有效措施，成人如何选择合适自己的疫苗？ 山东省疾控中心主任医师张丽表示，我国成人可以接种的疫苗种类很多，比如可以预防呼吸道传染 病的流感疫苗、肺炎球菌疫苗、新冠疫苗、麻疹-风疹-腮腺炎三联疫苗，预防肠道传染病的甲肝疫苗、 戊肝疫苗、霍乱疫苗，还有预防动物源性传染病的狂犬病疫苗、出血热疫苗和乙脑 ...

缪因知／文 尹某东是科兴生物的创始人及长期实际运营者，他曾参与研制SARS灭活疫苗、甲型H1N1流感疫苗、手足口病疫苗和新型冠状病毒疫苗。李某强是医学博士 出身的投资人，此前曾支持科兴生物另一名前董事长潘爱华与尹某东对抗。 作为上市公司的科兴生物，是北京科兴生物制品有限公司（下称"北京科兴"）的母公司，北京科兴控股的北京科兴中维生物技术有限公司是新冠疫苗的主要 供应商。2021年至2022年，科兴生物营收超1300亿元，净利润超960亿元。7月10日，科兴生物发放第一轮每股55美元的现金股息，分红总额为39.5亿美元 （约280亿元人民币）。根据公司计划，后续三轮分红总额将超过500亿元人民币。 上市公司科兴生物注册于加勒比海小岛国、英联邦成员国安提瓜和巴布达。注册地指公司创立人提交文件设立公司的地方，不等同于公司主要营业地，公司 国籍即注册地。在法律和现实世界中，安提瓜和巴布达是一个无足轻重的国家，其法制属英美法系，但具体法律规定鲜为人知。人们选择在此注册公司，主 要因其是避税天堂之一，不对当地注册公司征收所得税，很多公司会在这些避税地注册壳公司，以方便上市流程的操作。鉴于准确查询安提瓜的法律法规和 公司披 ...

Core Insights - Moderna announced a global workforce reduction of approximately 10%, which translates to nearly 800 employees, bringing the total number of employees below 5,000 by the end of the year [1][3] - The decision to cut jobs is driven by a significant decline in vaccine sales revenue, with the company's stock price dropping over 75% in the past year and market capitalization plummeting from nearly $200 billion to around $11 billion, a decrease of over 90% [3] Financial Pressure and Strategic Adjustments - To address the revenue decline, Moderna has implemented several cost-cutting measures, including a plan to reduce annual operating expenses by approximately $1.5 billion by 2027 [3] - The company also canceled plans to build an mRNA drug manufacturing facility in Japan due to changes in the global and Japanese business environment, indicating a strategic retreat from non-core business investments [3] Market Environment Challenges - Changes in U.S. health policy have directly impacted Moderna's business, including the withdrawal of long-term vaccination recommendations for children and pregnant women, which has narrowed the market for its latest vaccine [4] - The termination of a contract for developing an avian flu vaccine further constricts the company's business scope [4] - Moderna's second major product, the respiratory syncytial virus vaccine, has not gained significant market attention, leading to a downward revision of the company's revenue expectations for the year [4] - The timeline for achieving breakeven has been pushed from 2026 to 2028 due to underperformance in sales [4] - Despite these challenges, the CEO remains optimistic, highlighting that Moderna currently has three approved products and up to eight more expected to be approved within the next three years [4]

Core Viewpoint - Moderna's stock experienced a significant drop of over 10%, trading at $26.56, following the announcement of its second-quarter financial results which revealed a net loss of $825 million, or $2.13 per share, which was better than the expected loss of $2.97 per share [1] Financial Performance - The company's revenue from COVID-19 vaccine sales declined by 41% year-over-year, amounting to $140 million, which exceeded the expected revenue of $110 million [1] - In the same quarter of the previous year, Moderna reported a net loss of $1.3 billion, or $3.33 per share [1] Revenue Guidance - Due to delays in vaccine shipments to the UK, Moderna has revised its revenue guidance for 2025, now expecting annual revenue to be between $1.5 billion and $2.2 billion, a reduction of $300 million from earlier projections [1]

Core Viewpoint - Moderna is facing significant financial challenges due to declining sales of its COVID-19 vaccines, leading to a 10% workforce reduction and a stock price drop of over 75% in the past year [3][4]. Group 1: Financial Performance - Moderna announced a workforce reduction of nearly 1,000 employees, aiming to reduce its total staff to approximately 5,000 by the end of the year due to ongoing sales declines [3]. - The company's market capitalization has plummeted from nearly $200 billion at the peak of the pandemic to about $11 billion currently [3]. - Moderna plans to cut annual operating expenses by approximately $1.5 billion by 2027 [3]. Group 2: Product Development and Strategy - Despite the ongoing challenges, Moderna remains committed to developing new COVID-19 vaccines, with the FDA recently approving its third vaccine targeting new variants [3]. - The company has the potential to launch up to eight new products in the next three years [3]. - In contrast, BioNTech has successfully diversified its product pipeline and adjusted its strategy post-pandemic, leading to a stock price increase of nearly 25% over the past year and a market cap exceeding $25 billion [4][5]. Group 3: Market Comparison - BioNTech's strategy includes investing in licensing deals and diversifying into emerging fields like antibody-drug conjugates (ADCs), which has garnered investor confidence [4][5]. - Moderna's reliance on vaccine sales and its delayed product diversification strategy has raised concerns among investors about its long-term viability [5].

Core Viewpoint - The article discusses the internal conflicts within Sinovac Biotech, highlighting the company's significant financial performance and the ongoing power struggle among its shareholders and board members [5][18][21]. Group 1: Company Overview - Sinovac Biotech, known for its COVID-19 vaccine, has reported revenues exceeding 130 billion yuan and a net profit of over 96 billion yuan from 2021 to 2022, resulting in a net profit margin of approximately 73.8% [11][16]. - The company has been suspended from trading for six years due to internal disputes, indicating ongoing governance issues [21]. Group 2: Shareholder Conflict - A recent shareholder meeting in Antigua and Barbuda involved a proposal to remove current board members and elect new candidates nominated by SAIF Partners, reflecting deep divisions among shareholders [18][22]. - The company announced a massive special dividend payment of up to 7.5 billion USD, leaving it with 2.8 billion USD in cash after the distribution [22][23]. Group 3: Historical Context - The founder, Weidong Yin, has a background in public health and has been pivotal in the company's development since its establishment in 2001 [42][62]. - Sinovac's history includes rapid advancements in vaccine development, notably during the SARS outbreak, which laid the groundwork for its later success with COVID-19 vaccines [60][61].

Core Viewpoint - The delayed dividend distribution from Sinovac Biotech has resulted in over 2 billion RMB cash dividends for at least four investors, with a staggering dividend yield of 850% based on the stock price at the time of suspension [1][2]. Group 1: Dividend Distribution - On July 10, Sinovac Biotech announced a cash dividend of $55 per share, totaling approximately $3.95 billion (around 280 billion RMB) based on 71.86 million total shares [5]. - The dividend distribution is seen as a significant return for long-term investors, who have been unable to trade shares in the secondary market since the company was suspended from NASDAQ in February 2019 due to governance issues [5][11]. Group 2: Shareholder Dynamics - Major shareholders benefiting from the dividend include: 1. Strong New Capital, approximately $688 million (about 4.93 billion RMB) [9]. 2. Sequoia Capital, approximately $593 million (about 4.25 billion RMB) [9]. 3. Yin Weidong, approximately $350 million (about 2.5 billion RMB) [9]. 4. Dinghui Investment, approximately $330 million (about 2.36 billion RMB) [9]. 5. Shangrong Capital and Weiwang Capital, each approximately $320 million (about 2.33 billion RMB) [9]. Group 3: Governance and Control Struggles - Sinovac Biotech has been embroiled in a control struggle for seven years, with two competing boards of directors and claims of legitimacy from both sides [3][16]. - The company must submit a compliance rectification plan to NASDAQ by July 15 to avoid delisting risks [3]. - The ongoing disputes have led to a complex situation where two boards, led by different chairpersons, claim authority over the company [16][17]. Group 4: Legal and Regulatory Context - The special shareholders' meeting held on July 8 was marked by significant legal disputes regarding voting rights, particularly concerning the participation of Weiwang Capital and Shangrong Capital [19][22]. - The outcome of the meeting resulted in the election of a new ten-member board led by Yan Yan, which has been contested by the opposing faction [15][16]. - The legitimacy of the board changes and the associated legal battles have been ongoing since 2018, with multiple court rulings impacting the governance structure of Sinovac Biotech [21][22].

Core Viewpoint - The article discusses the significant cash dividend of 28 billion RMB (approximately 4.5 billion USD) announced by Sinovac Biotech, which comes after a prolonged six-year suspension of trading due to internal governance disputes and control struggles within the company [2][3][4]. Company Overview - Sinovac Biotech, a leading vaccine manufacturer, has faced a seven-year power struggle involving key figures such as Yin Weidong, Li Jiaqiang, and Pan Aihua [4][19]. - The company reported revenues exceeding 130 billion RMB (approximately 20 billion USD) and net profits over 96 billion RMB (approximately 15 billion USD) from 2021 to 2022 [4]. Dividend Details - The announced dividend of 55 USD per share translates to a total payout of approximately 39.5 billion USD (280 billion RMB) based on 71.86 million total shares [6]. - The dividend yields an astonishing 850% based on the stock price at the time of suspension [4]. Shareholder Distribution - Major shareholders receiving significant dividends include: - 1Globe Capital and related parties: approximately 6.88 billion USD (49.3 billion RMB) - Sequoia Capital: approximately 5.93 billion USD (42.5 billion RMB) - Yin Weidong: approximately 3.5 billion USD (25 billion RMB) - Dinghui Investment: approximately 3.3 billion USD (23.6 billion RMB) [7]. Governance Disputes - As of the dividend announcement, Sinovac Biotech is facing dual claims of authority from two boards and chairpersons, complicating the governance situation [4][5]. - The company must submit a compliance rectification plan to NASDAQ by July 15 to avoid potential delisting [5]. Legal and Operational Context - The dividend was proposed by a small shareholder, Hengrun Investment, which highlighted that over 10 billion USD in cash remained on the company's books after the dividend [10]. - The ongoing legal disputes regarding the legitimacy of the boards have led to a complex situation where two boards claim legitimacy, with the recent special shareholders' meeting resulting in a new board led by Yan Yan [13][14][18]. Historical Context - The power struggle dates back to 2016, with multiple board changes and legal battles over the company's governance structure, culminating in a ruling in early 2025 that recognized a new board led by Li Jiaqiang [19][20].

Core Viewpoint - Moderna's stock increased by 3.8% following the full approval of its COVID-19 vaccine by the U.S. Food and Drug Administration (FDA) for children aged 6 months to 11 years [1] Company Summary - Moderna received comprehensive approval from the FDA for its COVID-19 vaccine for the pediatric age group of 6 months to 11 years [1] Industry Summary - The approval signifies a significant milestone in the vaccination efforts against COVID-19, particularly for younger populations, potentially impacting public health strategies and vaccine uptake [1]

Group 1 - The U.S. regulatory agency has approved Moderna's COVID-19 vaccine for children under 12 at high risk, but the scope of eligibility has been narrowed compared to previous guidelines [1] - Under Robert F. Kennedy Jr.'s leadership, the U.S. health department has implemented measures to limit the use of COVID-19 vaccines for children, contrasting with the previous recommendation for vaccination for all individuals aged 6 months and older [1] - Public health experts express concerns that limiting vaccine access may pose risks to children under 2 years old, who are more susceptible to COVID-19 infection [1] Group 2 - Only 13% of children received the COVID-19 vaccine in the last quarter, which is half the vaccination rate of adults [2] - Over 150 children under 18 have died from COVID-19 in the year leading up to August 2024, indicating a serious risk for children [2] - Approximately 6 million American children may experience long-term effects from COVID-19, including an increased risk of developing type 2 diabetes [2] Group 3 - Moderna's stock price increased by over 3% in early trading [3]